Cellectis (NASDAQ:CLLS) Price Target Cut to $5.00 by Analysts at Barclays

Cellectis (NASDAQ:CLLS - Free Report) had its target price trimmed by Barclays from $7.00 to $5.00 in a research note released on Tuesday morning, Benzinga reports. The firm currently has an overweight rating on the biotechnology company's stock.

Separately, StockNews.com started coverage on shares of Cellectis in a research report on Tuesday. They issued a "sell" rating on the stock.

Cellectis Price Performance

Shares of NASDAQ:CLLS traded up $0.04 on Tuesday, hitting $1.80. The company's stock had a trading volume of 185,677 shares, compared to its average volume of 48,472. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.92 and a quick ratio of 1.92. The company has a 50-day simple moving average of $2.09 and a 200 day simple moving average of $2.28. The company has a market capitalization of $100.05 million, a PE ratio of -1.38 and a beta of 3.10. Cellectis has a 1 year low of $1.75 and a 1 year high of $3.77.

Cellectis (NASDAQ:CLLS - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.03). The business had revenue of $18.05 million during the quarter, compared to the consensus estimate of $5.00 million. Cellectis had a negative return on equity of 78.90% and a negative net margin of 401.83%. During the same quarter in the previous year, the firm posted ($0.31) earnings per share. Sell-side analysts forecast that Cellectis will post -0.54 EPS for the current fiscal year.

Institutional Investors Weigh In On Cellectis

Several large investors have recently bought and sold shares of the business. Principal Financial Group Inc. boosted its stake in shares of Cellectis by 2.9% in the second quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company's stock worth $817,000 after acquiring an additional 12,467 shares during the period. XTX Topco Ltd purchased a new position in shares of Cellectis in the 2nd quarter worth approximately $29,000. First Affirmative Financial Network purchased a new stake in shares of Cellectis in the third quarter valued at $45,000. Finally, Long Focus Capital Management LLC raised its position in Cellectis by 2.9% in the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company's stock worth $8,634,000 after purchasing an additional 130,000 shares during the period. 63.90% of the stock is currently owned by institutional investors.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.